2014 Equity Pricing Sales 
Startup Professionals Musings
JANUARY 4, 2015
If you don’t have a destination, don’t waste your money trying to get there, and don’t expect anyone to support you along the way Projecting financials is a natural extension of the homework every entrepreneur needs to do on customer opportunity size, product costs, pricing, competition and customer value. Forecast sales-volume expectations.
socalTECH
DECEMBER 11, 2017
In 2014, we raised quite a bit of money from St. The company has grown about 200 percent since 2014, in terms of revenue. Really, we're the sales and marketing arm of those companies. We sold that to a very large private equity company. They invested in 2014, and asked me to meet with Dallas Imbimbo, the CEO and Founder.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Both Sides of the Table
SEPTEMBER 28, 2014
by Michael Woolf that is worth any startup founder reading to get a sense of perspective on the reality warp that is startup world during a frothy market such as 1997-1999, 2005-2007 or 2012-2014. So money spent should add equity value or create IP that eventually will. (it is also the title of a fabulous book from Internet 1.0
Both Sides of the Table
APRIL 25, 2011
Early in a services business there is usually no profits as the company reinvests in hiring people to grow, but by $20 million in sales the company should at least be pulling in 10% profits (if not more) depending on how much is reinvested. That is $12 million in profits over 3 years. It’s pure irony.
Tech Zulu Event
OCTOBER 29, 2015
That includes e-commerce retailers, which continue to claim a growing slice of overall retail sales. Last year alone, online holiday sales rose 15% over 2013 figures, including increases of 32% on Thanksgiving, 26% on Black Friday, and 17% on Cyber Monday. Home values have been rising lately, and analysts expect that to continue.
Xconomy
JUNE 3, 2016
Merck also saw some expected fruits of its 2014 big-ticket acquisition of Cubist Pharmaceuticals wither away this week, as the Supreme Court wouldn’t reverse a decision that shaved years off the patent life of the top-selling antibiotic daptomyicin (Cubicin). The drug has a list price of $69,350 per patient, per year.
Both Sides of the Table
SEPTEMBER 5, 2012
This time by the efforts of Adeo Ressi to introduce a new kind of structure called “ convertible equity.” My initial reaction to Adeo when we spoke was that while it may have solved some issues (debt versus equity) it didn’t solve the ones that I’ve been warning entrepreneurs about most loudly.
Expert insights. Personalized for you.
102 
Let's personalize your content